Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
G protein-coupled receptor class 5 member D (GPRC5D) is a class C orphan GPCR predominantly expressed in multiple myeloma cells and hard keratinized tissues like hair and nails. Its limited expression in most normal human tissues makes it an attractive therapeutic target for multiple myeloma. Several immunotherapies, including bispecific antibodies and CAR T-cell therapies, are being developed against GPRC5D. Overexpression in bone marrow correlates with poor prognosis for MM patients.
Redirects T cells to kill GPRC5D+ MM cells by binding both CD3 on T cells & GPRC5D; Binds ECLs/TM domains of dimeric GPRC5D; Engineered T cells targeting surface-expressed GPRC5D
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on G protein-coupled receptor class 5 member D (None).